Auris Medical : development of novel pharmaceutical therapies to prevent or treat severe inner ear disorders like tinnitus and hearing loss

 

 

Investor Relations

Corporate Profile

We at Auris Medical are dedicated to developing novel pharmaceutical products for the treatment of inner ear disorders and mental health supportive care.

We are focused on the development of intranasal betahistine for the treatment of vertigo (AM-125) and for the treatment of antipsychotic-induced weight gain and somnolence (AM-201). This program is currently in Phase 1.

In addition Auris Medical has two Phase 3 programs under development: AM-111 for acute inner ear hearing loss and Keyzilen® (AM-101) for acute inner ear tinnitus.

 

Stock Quote

View more

Latest Press Releases

Read more

Upcoming Events
There are currently no events scheduled.

Various statements that Auris Medical Holding makes on this website about the company's future expectations, plans, and prospects constitute forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. The terms 'may,' 'will,' 'could,' 'anticipate,' 'plan,' 'continue,' 'project,' 'intend,' 'estimate,' 'believe,' 'expect,' and similar expressions are intended to identify forward-looking statements. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors.

In addition, any forward-looking statements represent the company's views only as of the date such statements are made and should not be relied upon as representing our views as of any subsequent date. While the company may elect to update these forward-looking statements at some point in the future, the company specifically disclaims any obligation to do so, even if its views change. Therefore, you should not rely on these forward-looking statements as representing the company's views as of any date subsequent the date such statements are made.

Investors